In this special guest post Kevin Chen, Co-founder & CEO, Hyasynth Bio, a precision fermentation startup producing sustainable cannabinoids, and Benjamin Joffe, Partner at SOSV make the case for European CBD biomanufacturing By now, many have heard about Cannabidiol, better known as CBD, the non-psychoactive cannabinoid derived from the cannabis plant and discovered in 1940. You can find it in products ranging from edible gummy bears to skin oil, for purposes such as pain or anxiety relief, cognition, acne treatment, or sleep aid. The FDA-approved prescription medicine Epidiolex containing CBD is currently being used by over 1 million people with hard-to-treat epilepsies. Scientific publications are multiplying – exploring many more therapeutic applications for conditions such as diabetes and arthritis – and finally providing clinical proof of some of the effects that have been observed for years. Investment in cannabis startups has been on fire, both by a number of deals and amounts raised, and 2021 is surpassing 2020 by a long shot, with over 200 deals by mid-October, including massive rounds like Dutchie’s $350 million Series D and Jane Technologies’s $100 million Series C. Scientific publications about CBD since 1980.
420 Intel – Marijuana Industry News, 04/20/2022 20:00:00